Elderly (> 70 years) Multiple Myeloma Patients Benefit Equally from Autologous Hematopoietic Stem Cell Transplantation When Compared to Younger Patients
Article Sidebar
Main Article Content
Abstract
Autologous Hematopoietic Stem Cell Transplantation (AHSCT) performed after induction therapy is the standard of care for newly diagnosed Multiple Myeloma (MM) patients who qualify. Our institution has performed AHSCT for MM since 1991, and in this study, we sought to retrospectively examine the outcomes of 303 MM patients who underwent AHSCT from 1991-2021. We focused on Overall Survival (OS) and Progression-Free Survival (PFS) in patients in addition to Landmark survival (1-year post-transplantation). We found that in elderly patients > 70 years of age there was no significant difference in OS at 12 years, with 51% for patients < 70 years of age and 50% > 70; these were the same numbers for PFS at 12 years as well. We also found that median overall survival is improving overall with each decade in our transplanted MM patients with patient survival improved to over > 80% regardless of age at 7 years, when the previous median overall survival was 6 - 6.6 years before 2001. Given our findings, supported by others, we show that survival is continually improving over time in MM AHSCT patients and that AHSCT can be performed safely with equivalent landmark and long-term PFS and OS in patients of advanced age.
Article Details
Copyright (c) 2024 Prabhakar N, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Stem Cell Therapy and Transplantation is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Stem Cell Therapy and Transplantation is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008 Mar 15;111(6):2962-2972. Available from: https://doi.org/10.1182/blood-2007-10-078022
Alwall N. Urethane and stilbamidine in multiple myeloma: Report on two cases. Lancet. 1947;2(6472):388. Available from: https://doi.org/10.1016/s0140-6736(47)90375-9
Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. Annals of the New York Academy of Sciences. 1958;68(3):1128-1132. Available from: https://doi.org/10.1111/j.1749-6632.1958.tb42675.x
Mass RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep. 1962;16:257-259. Available from: https://pubmed.ncbi.nlm.nih.gov/14470881/
Osgood EE. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep. 1960;9:1-10. Available from: https://pubmed.ncbi.nlm.nih.gov/13731417/
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-1571. Available from: https://doi.org/10.1056/nejm199911183412102
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-2617. Available from: https://doi.org/10.1056/nejmoa030288
Osserman EF, DiRe LB, DiRe J, Sherman WH, Hersman JA, Storb R. Identical twin marrow transplantation in multiple myeloma. Acta Haematol. 1982;68(3):215-223. Available from: https://doi.org/10.1159/000206984
Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horwitz L. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987 Sep;70(3):869-872. Available from: https://pubmed.ncbi.nlm.nih.gov/3304465/
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91-97. Available from: https://doi.org/10.1056/nejm199607113350204
Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 Mar 27;348(13):1875-1883. Available from: https://doi.org/10.1056/nejmoa022340
Lehners N, Becker N, Benner A, Pritsch M, Löpprich M, Mai EK, et al. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Med. 2018;7(2):307-316. Available from: https://doi.org/10.1002/cam4.1283
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1;111(5):2516-2520. Available from: https://doi.org/10.1182/blood-2007-10-116129
Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020;4(2):422-431. Available from: https://doi.org/10.1182/bloodadvances.2019000524
Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer. 2010;46(1):160-169. Available from: https://doi.org/10.1016/j.ejca.2009.07.006
Oliver-Caldes A, Soler-Perromat JC, Lozano E, Moreno D, Bataller A, Mozas P, et al. Long-term responders after autologous stem cell transplantation in multiple myeloma. Front Oncol. 2022;12:936993. Available from: https://doi.org/10.3389/fonc.2022.936993
Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, et al. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024;14(1):82. Available from: https://doi.org/10.1038/s41408-024-01062-2
Paquin A, Visram A, Kumar SK, Gertz MA, Cantwell H, Buadi FK, et al. Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer J. 2020;10:87. Available from: https://doi.org/10.1038/s41408-020-00353-8
Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, et al. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020 Dec 1;126(23):5077-5087. Available from: https://doi.org/10.1002/cncr.33171
Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014;20(11):1796-1803. Available from: https://doi.org/10.1016/j.bbmt.2014.07.013
El Cheikh J, Kfoury E, Calmels B, Lemarie C, Stoppa AM, Bouabdallah R, et al. Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2011;4(1):30-36. Available from: https://doi.org/10.5144/1658-3876.2011.30
Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol. 2008 Aug;83(8):614-617. Available from: https://doi.org/10.1002/ajh.21191
Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma. 2012;53(1):118-22. Available from: https://doi.org/10.3109/10428194.2011.606942
Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007;39(5):279-283. Available from: https://doi.org/10.1038/sj.bmt.1705580
Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769-1773. Available from: https://doi.org/10.1001/jamaoncol.2019.2055
Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37(7):589-597. Available from: https://doi.org/10.1200/jco.18.00685
Gehan EA. A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika. 1965;52(3-4):203-224. Available from: https://doi.org/10.2307/2333825
Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, et al. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013;11(1):11-17. Available from: https://doi.org/10.6004/jnccn.2013.0004
Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, et al. Autologous hematopoietic cell transplantation in patients with multiple myeloma: Effect of age. Clin Lymphoma Myeloma Leuk. 2017;17(3):165-172. Available from: https://doi.org/10.1016/j.clml.2016.11.006
Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000 May;25(5):533-539. Available from: https://doi.org/10.1038/sj.bmt.1702188
Chari A, Palumbo A, Mateos MV, et al. Daratumumab plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Patients with Multiple Myeloma (NDMM): Final Analysis of Griffin Among Clinically Relevant Subgroups. Blood. 2022;140(Supplement 1):7278-7281. Available from: https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022